Mostrar el registro sencillo del ítem
| dc.contributor.author | Mahe, Isabelle | |
| dc.contributor.author | Sterpu, Raluca | |
| dc.contributor.author | Bertoletti, Laurent | |
| dc.contributor.author | López-Jiménez, Luciano | |
| dc.contributor.author | Joan, Meritxell-Mellado | |
| dc.contributor.author | Trujillo-Santos, Javier | |
| dc.contributor.author | Ballaz, Aitor | |
| dc.contributor.author | Hernández-Blasco, Luis-Manuel | |
| dc.contributor.author | Javier-Marchena, Pablo | |
| dc.contributor.author | Monreal, Manuel | |
| dc.date.accessioned | 2026-10-21T06:12:29Z | |
| dc.date.available | 2026-10-21T06:12:29Z | |
| dc.date.issued | 2015-06-15 | |
| dc.identifier.citation | Mahé I, Sterpu R, Bertoletti L, López-Jiménez L, Mellado Joan M, Trujillo-Santos J, et al. Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices? Lonser RR, editor. PLoS ONE. 15 de junio de 2015;10(6):e0128741. doi:10.1371/journal.pone.0128741 | |
| dc.identifier.issn | 1932-6203 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/28766 | |
| dc.description.abstract | Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA) in non-cancer patients with venous thromboembolism (VTE), and long-term therapy with low-molecular weight heparin (LMWH) for those with cancer. We used data from RIETE (international registry of patients with VTE) to report the use of long-term anticoagulant therapy over time and to identify predictors of anticoagulant choice (regarding international guidelines) in patients with- and without cancer. Among 35,280 patients without cancer, 82% received long-term VKA (but 17% started after the first week). Among 4,378 patients with cancer, 66% received long term LMWH as monotherapy. In patients without cancer, recent bleeding (odds ratio [OR] 2.70, 95% CI 2.26-3.23), age >70 years (OR 1.15, 95% CI 1.06-1.24), immobility (OR 2.06, 95% CI 1.93-2.19), renal insufficiency (OR 2.42, 95% CI 2.15-2.71) and anemia (OR 1.75, 95% CI 1.65-1.87) predicted poor adherence to guidelines. In those with cancer, anemia (OR 1.83, 95% CI 1.64-2.06), immobility (OR 1.51, 95% CI 1.30-1.76) and metastases (OR 3.22, 95% CI 2.87-3.61) predicted long-term LMWH therapy. In conclusion, we report practices of VTE therapy in real life and found that a significant proportion of patients did not receive the recommended treatment. The perceived increased risk for bleeding has an impact on anticoagulant treatment decision. | |
| dc.language.iso | eng | |
| dc.rights | Atribución/Reconocimiento 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/deed.es | * |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Aged, 80 and over | |
| dc.subject.mesh | Anticoagulants/therapeutic use | |
| dc.subject.mesh | Drug Prescriptions/statistics & numerical data | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Fibrinolytic Agents/therapeutic use | |
| dc.subject.mesh | Follow-Up Studies | |
| dc.subject.mesh | Guideline Adherence | |
| dc.subject.mesh | Heparin, Low-Molecular-Weight | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Neoplasms/complications | |
| dc.subject.mesh | Time Factors | |
| dc.subject.mesh | Venous Thromboembolism/diagnosis/drug therapy/etiology | |
| dc.subject.mesh | Vitamin K/antagonists & inhibitors | |
| dc.title | Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices? | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 26076483 | |
| dc.relation.publisherversion | https://dx.plos.org/10.1371/journal.pone.0128741 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1371/journal.pone.0128741 | |
| dc.journal.title | Plos One |